Clinical trial

Minocycline for the Treatment of Early-Phase Schizophrenia

NCT00733057

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Minocycline Normalized identity: minocyclineView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo (200 mg/day) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Minocycline for the Treatment of Early-Phase Schizophrenia

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-08-01

PhasePHASE3

Conditions

Negative and Cognitive Symptoms in Schizophreniaunresolved

Interventions

MinocyclineDRUG · verified · RxNorm: minocycline

Placebo (200 mg/day)DRUG

Sponsors & collaborators

Shalvata Mental Health Centerlead sponsor

Abarbanel Mental Health Centercollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00733057 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.